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Edited by Felix WielandAbstract Macrophage migration inhibitory factor (MIF) binds
to c-Jun activation domain binding protein-1 (JAB1)/subunit 5 of
COP9 signalosome (CSN5) and modulates cell signaling and the
cell cycle through JAB1. The binding domain of JAB1 responsi-
ble for binding to MIF is unknown. We hypothesized that the
conserved Mpr1p Pad1p N-terminal (MPN) domain of JAB1
may mediate binding to MIF. In fact, yeast two hybrid (YTH)
and in vitro translation/coimmunoprecipitation (CoIP) analysis
showed that a core MPN domain, which did not cover the func-
tional JAB1/MPN/Mov34 metalloenzyme (JAMM) deneddy-
lase sequence, binds to MIF comparable to full-length JAB1.
YTH and pull-down analysis in conjunction with nanobead aﬃn-
ity matrix-assisted laser desorption ionization-time of ﬂight
(MALDI-TOF) mass spectrometry demonstrated that
MIF(50–65) and MPN are suﬃcient to mediate MIF–JAB1
interaction, respectively. Finally, endogenous CoIP of MIF–
CSN6 complexes from mammalian cells demonstrated that
MPN is responsible for MIF–JAB1 binding in vivo, and, as
CSN6 does not contain a functional JAMM motif, conﬁrmed
that the interaction does not require JAMM.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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light-dependent development [1]. CSN consists of 8 subunits;
accordingly, JAB1 is alternatively termed subunit 5 of COP9
signalosome (CSN5). CSN is widely conserved between species
and was also identiﬁed in eukaryotes, including human cells
[2–4]. The 8 subunits of CSN share sequence homology with
subunits of the 19S proteasome lid and with those of the trans-
lation initiation complex eIF3 [5]. Homology primarily comes
from the similarity of the so-called MPN (Mpr1p Pad1p N-
terminal) domain of CSN5 and CSN6, and from the PCI
(proteasome, COP9, eIF3) domain of subunits 1–4 and 7–8 [6].
In mammalian cells, CSN is involved in the regulation of
protein stability by cooperating with the 26S proteasome.
For example, CSN has been implicated in the regulation of
degradation of the transcription factors p27, p53, Id1, and
Id3 [7–9]. CSN-mediated phosphorylation followed by ubiqui-
tination appears to constitute a critical intermediate step dur-
ing these processes. The mechanism by which the CSN
contributes to ubiquitin-proteasome-mediated protein degra-
dation is complex and has not yet been ﬁnally resolved [4].
CSN exhibits a metalloprotease/isopeptidase activity centered
around its subunit JAB1/CSN5. CSN interacts with cullin-
based E3 ubiquitin ligases and it has been established that
through its isopeptidase activity, CSN removes the post-
translational modiﬁcation of a ubiquitin-like protein, neural
presursor cell expressed developmentally down-regulated 8
(Nedd8)/Rub1, from the cullin component of SCF ubiquitin
E3 ligase [4,10]. Accordingly, CSN has a deneddylation
activity. It is currently believed that CSN, through its deneddy-
lation activity, promotes cullin-dependent proteolysis in vivo
[4,11]. The deneddylation activity was mapped to the JAB1/
MPN/Mov34 metalloenzyme (JAMM) sequence motif of
JAB1/CSN5 and deneddylation of neddylated cullin 1 by
CSN is dependent on the presence of JAB1 [10]. The JAMM
motif consists of ﬁve polar residues that resemble the active site
residues of hydrolytic enzyme classes, particularly that of
metalloproteases; the prototypical JAMM consensus sequence
is EXnHS/THX7SXXD [10,12]. The His and Asp residues of
this conserved motif coordinate a zinc ion. Within the CSN
subunits, the JAMMmotif, which is also termed MPN+ motif,
is only present in JAB1/CSN5, but JAMM is found in certain
other MPN domain-bearing proteins outside the CSN, includ-
ing the 19S proteasome lid subunit POH1/Rpn11 [12–14].
Whereas JAB1/CSN5 is involved in deneddylation, POH1/blished by Elsevier B.V. All rights reserved.
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JAMM motif speciﬁes a catalytic center that deﬁnes a family
of zinc-dependent proteases that remove ubiquitin or ubiqui-
tin-like proteins from components of the ubiquitin-proteasome
degradation system.
JAMM stands for JAB1/MPN/Mov34 metalloenzyme,
indicating that the JAMM motif is located within the con-
served MPN/Mov34 domain of JAB1/CSN5. The precise
functions of MPN domains are unknown, but they are neces-
sary for proper interactions between subunits of the corre-
sponding protein complexes. MPN domain proteins in
eukaryotes include CSN5, CSN6, Rpn8/S12, Rpn11/POH1,
AMSH, and C6.1A [6,12]. The MPN domain spans up to
120–140 amino acid residues and is predicted to have an
a/b structure. It is typically present in the N-terminal part
of a protein. A core MPN region containing the three similar-
ity peaks I, II and III covers 90 residues [6,15]. Recently,
the 121 amino acid residue MPN domain-only protein
AF2198/AfJAMM was identiﬁed and crystallized from an
archaebacterium [16,17]. The obtained structure overall con-
ﬁrmed the predicted MPN structures and conﬁrmed JAMM
as a functional metalloprotease site.
That the MPN domain could serve as a conserved protein–
protein interaction module in mammalian cells, was recently
demonstrated experimentally. Tomoda et al. [18] showed that
the N-terminal half of JAB1/CSN5 (residues 1–190 including
the MPN domain) mediates the binding of JAB1 to the cell cy-
cle inhibitor p27. Similarly, DNA topoisomerase IIa interac-
tion with JAB1 is dependent on the MPN domain of JAB1,
as a deletion mutant of JAB1 missing sequence region 55–
190 does not bind to JAB1, while a C-terminal mutant span-
ning residues 1–190 strongly interacts [19]. Both for p27 and
DNA topoisomerase IIa, MPN-target protein interaction is
functionally important, regulating, among other eﬀects, p27
and DNA topoisomerase IIa degradation.
To date, more than 20 proteins have been identiﬁed to inter-
act with JAB1/CSN5. Among these proteins are other CSN
subunits that are in direct contact with JAB1 as well as target
proteins of the ubiquitin-proteasome degradation machinery.
However, JAB1 functions may reach beyond a role in protein
degradation. Accordingly, JAB1 (and the CSN) has been
implicated in the regulation of signal transduction pathways
and JAB1-interacting proteins include components of cell sig-
naling pathways, such as the b2-integrin LFA-1 and the cyto-
kine macrophage migration inhibitor factor (MIF) [20].
MIF is an evolutionary conserved 12.5 kDa protein that in
humans functions as a pleiotropic cytokine with a mostly pro-
inﬂammatory spectrum of action in the host immune response.
As such, MIF is a critical mediator of a number of immune
and inﬂammatory conditions (reviewed in [21]), including bac-
terial septic shock [22,23], rheumatoid arthritis [24], atheroscle-
rosis [25], and tumorigenesis [26]. MIF is unique among
cytokines, as it also has functions outside the immune system
(reviewed in [27]) and can act as a glucocorticoid antagonist
and endocrine factor [23,28].
Regulation of immune cell activity by MIF is at least in part
mediated through CD74. CD74 is the invariant chain (Ii) of
the major histocompatibility complex II (MHC II), but is also
expressed independently of MHC II on the plasma membrane.
Surface CD74 serves as a membrane receptor for MIF and is
involved in the stimulation of cell proliferation and ERK
MAPK signaling by MIF [29].Of note, an intracellular role of MIF could be related to its
catalytic properties, i.e., its thiol-protein oxidoreductase
(TPOR) activity, that is dependent on a Cys–Ala–Leu–Cys
(CALC, CXXC) motif [30–32]. In addition, the TPOR activity
of MIF could play a role in MIF-mediated inhibition of apop-
tosis and regulation of monocyte/macrophage activation
[31,33,34]. A MIF-derived TPOR motif-spanning peptide
exhibits MIF-like TPOR activity and mimics MIF cell-regula-
tory functions [34].
Intracellular functions of MIF also encompass its binding
to JAB1/CSN5. Both endogenous intracellular MIF and
extracellular MIF following endocytosis can interact with
JAB1 and MIF can regulate certain of the cellular activities
of JAB1 [35]. Through binding to JAB1, MIF antagonizes
stimulation of activator protein-1 (AP-1) activity by JAB1.
MIF inhibits both JAB1-induced c-Jun-N-terminal kinase
(JNK) activity and AP-1 transcriptional activation. Also,
the JAB1-mediated overcoming of cell cycle arrest and
JAB1-induced p27 degradation is counter-regulated by
MIF. Accordingly, MIF stabilizes p27 levels in G1-arrested
cells [35]. MIF–JAB1 interaction appears to serve a critical
role during inﬂammatory processes, as such complexes were
speciﬁcally observed in atherosclerotic plaque tissue [25]
and pituitary tumors [36].
On the side of MIF, sequence region 50–65 is important for
the interaction with JAB1, as MIF peptide 50–65 competes
with full-length MIF for JAB1 binding [35], and because this
MIF-agonistic peptide directly binds to full-length JAB1 [34].
While the peptide spans the CXXC motif of MIF, it appears
that the cysteine residues themselves are not necessary for
mediating the interaction with JAB1, as a bis-serine variant
peptide also competes with recombinant human MIF (rMIF)
and also directly binds to JAB1 [34,35]. In contrast, it has
not been addressed which domain or sequence region of
JAB1 contributes to MIF–JAB1 interaction.
We hypothesized that the MPN module of JAB1 which was
reported previously to be important for protein–protein inter-
actions, could mediate the binding of MIF to JAB1. Thus, in
the current study we devised a core MPN domain and exam-
ined by yeast two hybrid (YTH) and coimmunoprecipitation
(CoIP) analysis, whether this domain participates in the inter-
action. To further deﬁne the MIF–JAB1 binding event, the
CXXC-spanning MIF peptide 50–65 and its bis-serine variant
were included in the investigation, and the potential physiolog-
ical relevance of MPN-mediated MIF–JAB1 interaction was
addressed by endogenous interaction studies in vivo.2. Materials and methods
2.1. Cell culture and miscellaneous reagents
General cell culture reagents such as media, supplements, antibiot-
ics, and serum were from Gibco Invitrogen Corporation (Karlsruhe,
Germany). Human epithelial kidney cells (HEK293) were bought from
the German Society for Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany) and were maintained by routine protocols
in Dulbeccos modiﬁed Eagle medium supplemented with 10% fetal
calf serum (FCS), 1% penicillin–streptomycin, and 5 mM of L-gluta-
mine. Cells were subcultured 2–3 times a week and passages 5–15 were
used for the experiments. All cell culture experiments were performed
at 37 C in a humidiﬁed incubator with 5% CO2.
Miscellaneous reagents such as chemicals and salts were from Sigma–
Aldrich Chemicals (Taufkirchen, Germany). All reagents were of the
highest grade commercially available.
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We previously identiﬁed the interaction between MIF and JAB1 by
YTH screening [35]. Applying an essentially identical YTH system
(Matchmaker 2; Clontech, Heidelberg, Germany), the coding region
of the human MIF gene was fused in-frame to the GAL4 DNA bind-
ing domain (GAL4-BD) using the pAS2-1 vector as described previ-
ously [35]. The resulting bait plasmid, pMIF-BD, was used to
examine the interaction between human MIF and the MPN domain
of JAB1 by YTH screening essentially following the manufacturers
protocol. A core region of the MPN domain covering amino acids
53–142 but not spanning the full JAMM motif was fused in-frame to
the GAL4 DNA activation domain (GAL4-AD) using the pACT2 vec-
tor (pMPN-AD). Cloning of the full-length human JAB1 gene into
pACT2 was described previously [35]. The MPN insert was generated
from this construct using an EcoRI site-containing forward primer 5 0-
CGG AAT TCA TGA AGT ACT GCA AAA TCT CAG CAT TG-3 0
and the SacI site-containing reverse primer 5 0-GGA GCT CCT AAT
AGC CAG GGT GGC TAT GAT ACC AC-3 0. For structure func-
tion analysis purposes, MIF mutants were also cloned into pAS2-1.
The mutants used were the tautomerase-dead mutant MIF mutant
with Pro2 exchanged for Ala (P2AMIF) and the oxidoreductase-dead
mutant MIF mutant with Cys60 exchanged for Ser (C60SMIF) [37].
Mutant constructs in pAS2-1 were generated by amplifying the mutant
sequences from their corresponding pET11b vectors, using the same
cloning sites as for wild-type human MIF [35].
For cotransformations of the resulting bait and prey plasmids,
pMIF-BD (or the mutated MIF variants) and pMPN-AD (or pJA-
B1AD), respectively, yeast strain CG1945 was used when testing for
growth on His drop-out medium (Clontech) and strain Y190 was ap-
plied when testing for b-galactosidase activity. The following con-
structs were used as positive and negative controls for the
(co)transformations: pCL1, positive control plasmid encoding for
full-length wild-type GAL4 protein; pVA3-1/pTD1-1, cotransformed
positive control plasmids encoding for a p53-BD fusion protein in
pAS2-1 and a SV40 T-antigen-AD fusion protein in pACT-2, respec-
tively. (Co)transformations and YTH screens were performed essen-
tially as described by the manufacturer.
Selection for signiﬁcant interactions was carried out on Trp Leu
His medium and we tested positive clones containing GAL4 DNA
activation domain fusion proteins for b-galactosidase activity using
the ONPG (o-nitrophenyl b-D-galactopyranoside, Roche Diagnostics,
Mannheim, Germany) test. The ONPG test was performed essentially
following the method of Miller, except that an optimized yeast cell lysis
procedure using lyticase (5 U/ll in TE buﬀer, 200 ll/10 ml of cell sus-
pension) was applied [38]. Brieﬂy, the chromogenic substrate ONPG
was added in excess. After incubation at 30 C, the reaction was
stopped by raising the pH to 11 to inactivate b-galactosidase. Product
formation was determined spectrophotometrically and plotted inMiller
units.2.3. In vitro translation, coimmunoprecipitation and SDS–PAGE/
Western blot analysis
CoIPs were performed both following in vitro transcription/transla-
tion (IVT) reactions and from HEK293 kidney epithelial cell lysates.
For CoIPs from IVT lysates, rMIF and radioactively labeled MPN
were used. Biologically active natively folded rMIF was prepared as
described previously [35]. The MPN cDNA was ampliﬁed from pCI-
neo-JAB1 [35] using forward primer 5 0-CTA GCT AGC ATG AAG
TAC TGC AAA ATC TCA GCA TTG-3 0, containing an NheI site,
and reverse primer 5 0-CGG GAT CCC TAA TAG CCA GGG
TGG CTA TGA TAC CAC-3 0, containing a BamHI site, and was
fused into the pET11b vector (Novagen-Calbiochem, Heidelberg, Ger-
many). For IVT, the in vitro PBS Kit from RiNA GmbH (Berlin,
Germany) was used. Gene expression in this Escherichia coli-derived
cell-free protein biosynthesis system is under control of the T7 pro-
moter. Expressed target protein was radiolabeled by incorporation of
35S-methionine. 30 ll of the IVT lysate was diluted with phosphate-
buﬀered saline (PBS, pH 7.4), and rMIF added to give a ﬁnal volume
of 1045 ll. The incubation was divided and equal portions used for the
CoIP and control incubations. The solution was incubated by end-
over-end rotation for 1 h at room temperature. To pull-down
rMIF–35S–MPN complexes, a polyclonal rabbit anti-MIF antibody
(Ka565) was added and the incubation continued for 1 h at room tem-
perature by end-over-end rotation. The control was incubated identi-cally except that the anti-MIF antibody was omitted. Protein A
sepharose (Amersham-Pharmacia, Freiburg, Germany) was added
for 2 h (200 ll slurry blocked overnight with 5% dry-milk powder;
room temperature; end-over-end rotation). Washes (4 times) were per-
formed with 0.1 · HNT buﬀer (25 mM HEPES, pH 7.2, 1.5 mM
MgCl2, 2 mM EDTA, 3 mM DTT, 0.5% Triton X100; end-over-end
rotation for 5 min each). 35S–MPN coimmunoprecipitated with rMIF
was then revealed by SDS–PAGE electrophoresis in a 18% gel and,
upon drying of the gel, exposure of an X-ray screen.
Binding of MIF to CSN6 was examined by CoIP analysis of endog-
enous complexes from HEK293 cells. To be able to directly compare
the result of the MIF–CSN6 CoIP with a recently optimized CoIP of
MIF with JAB1 from HEK293 cells expressing both endogenous
JAB1 and ectopically overexpressed myc-tagged JAB1, MIF–CSN6
CoIPs were performed from HEK293 cells that were stably mock-
transfected with the pCIneo vector (Lue et al., submitted). Brieﬂy, sta-
ble transfections of HEK293 cells were performed as follows: cells were
transfected with the linearized pCIneo-mycJAB1 and pCIneo vectors
using the SuperFect transfection reagent (Qiagen, Hilden, Germany)
according to the manufacturers instructions. Cells were incubated with
800 lg/ml G418 for 2 weeks. Positive clones potentially carrying the
myc-tagged JAB1 sequence stably integrated in their genome were fur-
ther selected through treatment with 200 lg/ml of G418 for another 8
weeks. Positive clones were identiﬁed by Western blotting analysis.
HEK293neo cells were lysed in low stringency CoIP buﬀer (50 mM
Tris–HCl, pH 7.5, 15 mM EGTA, 100 mM NaCl, 0.1% Triton X100,
10% glycerin, 25 mM sodium ﬂuoride, 1 mM DTT, 1 · proteinase
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), 1 mM
sodium azide), 2 lg polyclonal rabbit anti-CSN subunit 6 antibody
(Biotrend, Ko¨ln, Germany) added, and the incubation continued for
1.5 h at 4 C. Milk powder-blocked (5% in PBS) protein A sepharose
beads (50 ll slurry) were washed with PBS and CoIP buﬀer and added
to the incubation. After 1 h at 4 C, beads were washed 3 times with
CoIP buﬀer. Bound protein was eluted by adding 1· reducing Nu-
PAGE sample buﬀer (SLB-DTT) and boiling. Precipitated proteins
were separated in 4–12% NuPAGE gels (Invitrogen, Karlsruhe, Ger-
many) and transferred to nitrocellulose. Coimmunoprecipitated
endogenous MIF was revealed by Western blotting using a polyclonal
rabbit anti-MIF antibody (Ka565) as described previously [35]. For
control, blots were redeveloped for CSN6 using the above antibody.
For comparison of MIF–CSN6 with MIF–JAB1 binding, CoIPs of
endogenous MIF–JAB1 complexes were performed from
HEK293mycJAB1 cells by a similar protocol, except that the mouse
monoclonal anti-JAB1 antibody 8H8.5 from Genetex (San Antonio,
TX, USA) and protein G sepharose beads were used for the CoIP.
In these experiments, complexes of overexpressed mycJAB1 and
MIF were also analyzed by co-adding an anti-myc 9E10 mouse mono-
clonal antibody (Roche Diagnostics), but the resulting bands were not
used for the comparison. Detection of bands was achieved by ECL
chemoluminescence. Incubation with the corresponding peroxidase-
conjugated secondary antibody was performed at room temperature
for 2 h at a dilution of 1:10 000 in blocking buﬀer. As ECL reagent,
SuperSignal West Dura (Pierce-Perbioscience, Bonn, Germany) was
used. Staining was measured by the LAS-3000 imager (Raytest, Iso-
topenmessgera¨t GmbH, Straubenhardt, Germany).
2.4. Nanobead pull-down and mass spectrometry analysis
To test the interaction of the MPN domain with MIF peptide
MIF(50–65), silica-streptavidin-nanobeads (SAv-beads) and biotin-
MIF(50–65) were applied. A bis-serine variant of biotin-MIF(50–65),
with the two cysteine residues of the CXXC motif of MIF exchanged
for serine, was used for comparison. The synthesis of biotinylated
MIF(50–65) and biotinylated bis-serine-MIF(50–65) has been de-
scribed previously [34]. SAv-nanobeads were developed by the Tovar
group as described previously [39] and had a biotin binding capacity
of 800 pmol/mg beads. For interaction and pull-down, 0.5 ll of a
1 mg/ml biotin-MIF(50–65) solution (250 pmol in 20 mM sodium
phosphate buﬀer, pH 7.2) and 10 ll of an IVT reaction expressing
non-radioactively labeled MPN domain (see above; corresponding to
an estimated amount of 95 pmol) were added to a dispersion of
250 lg SAv-beads in 250 ll PBS (200 pmol Biotin binding capacity).
PBS was added to 500 ll and the reaction incubated for 3 h at room
temperature under gentle shaking conditions. Control incubations con-
tained identical amounts of beads and MPN but no biotin-MIF(50–
65).
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Triton X100 (10 min shaking at 5 C each), with 2 · 1 ml PBS
(10 min shaking at 5 C each), and with 1 · 1 ml double-distilled water
(10 s vortexing). After the ﬁnal washing step, the pellet was resus-
pended in 10 ll water and this solution used directly for the nanobead
aﬃnity matrix-assisted laser desorption ionization-MS (MALDI-MS)
analysis.
For the mass spectrometry measurements, a linear LD-time of ﬂight
(LD-TOF) system (HP G 2025A from GSG Mess-und Analysengera¨te
GmbH, Bruchsal, Germany) was used. The instrument was equipped
with a time lag focusing (TLF) unit and a digital oscilloscope (LeCroy
9350) for data acquisition. Measurements were performed at 20 kV
acceleration power and under optimized TLF conditions for a center
mass of 10 445 Da using the positive ion mode. For the analyses, a
so-called sandwich preparation was used: 0.5 ll sinapinic acid
(20 mg/ml in 99% acetone) was added to a MALDI target and air-
dried. Subsequently, 1–3 ll bead suspension was added in 1 ll steps
onto the dried matrix layer and dried under vacuum (Hewlett-Packard
Sample Prep Accessory). Onto the top-most layer, another 0.5 ll sina-
pinic acid (20 mg/ml 50% acetonitrile/0.1% triﬂuoroacetate (TFA)) was
pipetted and the mixture again air-dried. The measurements were per-
formed under ultra-vacuum conditions (5 · 107 Torr). For external
calibration, MALDI-MS analyses with the standard proteins horse
cytochrome C and horse myoglobin (Sigma–Aldrich) were performed
under the same conditions.3. Results
3.1. The MPN domain of JAB1 binds to MIF as assessed by
YTH and protein–protein interaction analysis in vitro
To test whether the MPN domain of JAB1 was necessary
for MIF–JAB1 interaction, a core MPN domain was cloned.
Core MPN (coreMPN) spanned residues 53–142 of human
JAB1, therefore encompassing a main structural core of
MPN including the three prominent similarity peaks I, II
and III according to Asano et al. [15]. CoreMPN contained
2a-helices and 3b-strands according to the secondary struc-
ture prediction method of Garnier et al. [40] and aligned rea-
sonably well with the MPN domain protein AF2198 of
A. fulgidus [16] as assessed by the NCBI conserved domain
search blast program (CD alignment; score: 38.4 bits).
CoreMPN did not cover the JAMM motif residues Ser150
and Asp153 and thus did not contain a functional JAMM
metalloprotease site [17].
First, the core MPN sequence was cloned into the pACT2
vector fused to the GAL4 DNA activation domain (MPN-
AD) and was used as the prey sequence in a YTH analysis
with full-length human MIF as bait (MIF-BD). Three inde-
pendent clones that grew following nutritional selection on
Leu/Trp CG1945 yeast cells (MIF/MPN1, MIF/MPN2.
MIF/MPN3), were further tested for growth on His drop-
out medium (Leu/Trp/His). All clones were found to
grow on this selection medium comparable to the positive
control p53/SV40. In contrast, combining MIF-BD with
GAL4-AD and Lamin-BD with MPN-AD did not result in
colony growth on triple drop-out medium (Fig. 1A). YTH
analysis by the liquid culture ONPG assay in Y190 yeast cells
was then applied to conﬁrm the observed MIF–MPN interac-
tion and to quantitate it. Fig. 1B shows that the MIF–MPN
interaction was weaker than that observed for p53–SV40.
This was expected, since the MIF–JAB1 interaction was pre-
viously found also to be weaker than that between p53 and
SV40 [35]. Furthermore, additional analysis by the ONPG as-
say demonstrated that the MIF–MPN interaction was essen-
tially identical in strength to that observed between MIF andfull-length JAB1, indicating together that coreMPN is suﬃ-
cient for mediating the interaction between MIF and JAB1
(Fig. 1C).
To conﬁrm the observed binding between MPN and MIF at
the protein level, CoIP analysis was performed. Since we were
unable to recombinantly express and purify MPN in suﬃcient
amounts from E. coli, radioactively labeled coreMPN was pro-
duced by IVT and incubated together with bacterially
expressed, puriﬁed, biologically active rMIF. Potential
35S–MPN–rMIF protein complexes were immunoprecipitated
with anti-MIF antibody and coprecipitated 35S–MPN ana-
lyzed by gel electrophoresis. Immunoprecipitation with anti-
MIF led to the detection of an MPN band that was markedly
stronger than that detected following a control incubation
without anti-MIF antibody, conﬁrming that speciﬁc 35S–
MPN–rMIF protein complexes had formed (Fig. 2).
Together with the YTH analyses, this indicated that core-
MPN mediates the binding of JAB1 to MIF and, because core-
MPN does not contain a complete JAMM motif, suggested
that MIF–JAB1 binding was independent of JAMM.3.2. MIF sequence 50–65 mediates binding to MPN
The sequence stretch 50–65 of MIF was previously shown to
compete with rMIF for JAB1 binding [35] and can directly
bind to JAB1 [34]. In addition, MIF(50–65) exhibits certain
MIF-agonistic eﬀects [34]. We therefore asked whether
MIF(50–65) was able to bind to the MPN domain of JAB1.
Biotinylated MIF(50–65) was prepared and incubated with
coreMPN that was produced by IVT. Formed complexes were
then subjected to pull-down analysis using the SAv-nanobeads
and coprecipitated MPN protein detected by mass spectrome-
try. Fig. 3 shows that MIF(50–65) markedly interacted with
coreMPN (upper/red spectrum), whereas in a control incuba-
tion containing the beads but no biotin-MIF(50–65)
(bottom/black spectrum) no MPN was detected by the MAL-
DI-MS analysis. Previous studies had shown that the binding
of MIF(50–65) to JAB1 is not dependent on the presence of
the two cysteine residues at positions 57 and 60, as a corre-
sponding bis-serine variant of MIF(50–65) bound to JAB1
similar to the wildtype peptide [34]. We therefore compared
the binding between biotin-MIF(50–65) and coreMPN with
that of biotin-bis-serine-MIF(50–65). MALDI-MS analysis re-
vealed that the variant peptide also bound to coreMPN (Fig. 3,
middle/blue spectrum). Binding of the variant peptide ap-
peared to be weaker than that of the wildtype peptide, but such
a quantiﬁcation is unsafe, since MALDI-MS analysis is only a
semi-quantitative method.
Binding of MIF(50–65) and its serine variant peptide to
coreMPN further conﬁrmed that MPN is suﬃcient to medi-
ate binding of JAB1 to MIF, but also showed that the re-
dox-active cysteines that are part of the CXXC sequence
stretch, are not required for the interaction between MPN
and MIF. YTH analysis using a CXXC variant of MIF,
C60SMIF, instead of wildtype MIF yielded no positive
clones on the triple-drop-out medium. It is currently unclear,
whether lack of a positive YTH result for C60SMIF is due
do a lack of interaction with MPN or whether it is due to
protein misfolding/aggregation and/or lower expression levels
of this mutant compared to the wildtype protein. To further
extend the structure function analysis of the MIF–MPN
interaction, we next asked whether the sequence motif
Fig. 1. Yeast two hybrid (YTH) analysis of the MIF–MPN interaction. (A) MIF interacts with the core MPN domain of JAB1/CSN5 in the YTH
assay. Growth of yeast transformants (strain CG1945) coexpressing wildtype human MIF and coreMPN on nutritional selection medium. Left,
overview of plate streaking proﬁle; middle, Leu+ Trp+ transformants were streaked on media lacking leucine and tryptophan (CG1945/Leu Trp);
right, transformants were streaked on triple-drop-out media (CG1945/Leu Trp His). Only the positive control p53-BD/SV40-AD and the three
MIF-BD/MPN-AD clones grow. (B) Quantiﬁcation of the MIF–MPN interaction in the YTH system by the liquid media assay according to Miller.
b-Galactosidase activity was determined by liquid media assay in strain Y190. Activity of the MIF-BD/MPN-AD samples is 3· lower than that of
p53-BD/SV40-AD, but signiﬁcantly higher than that of the negative controls GAL4-AD/MIF-BD and GAL4-AD/GAL4-BD. (C) Quantitative
comparison of the MIF–MPN interaction with that of MIF–JAB1 and P2AMIF–JAB1 and P2AMIF–MPN by YTH analysis. As in (B), the liquid
media assay was applied. Values in (B) and (C) are means ± S.D. of 3 determinations. Statistics were calculated by the two-sided students t test. The
diﬀerences in (B) between MIF/MPN and the positive and negative controls were signiﬁcant (P < 0.05). The diﬀerences between P2AMIF/MPN–
wtMIF/MPN and P2AMIF/JAB1–wtMIF/JAB1 in (C) were not signiﬁcant (P > 0.05).
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tomerase activity, was required for the interaction. The Pro-2
residue is critical for MIFs tautomerase site and its rele-
vance for the interaction between MIF and JAB1 has not
been investigated. We thus checked, whether the tautomerase
mutant P2AMIF was able to bind to JAB1 and MPN.
Quantitative YTH analysis demonstrated that P2AMIF sig-
niﬁcantly bound to both JAB1 and MPN (Fig. 1C). Binding
of P2AMIF to JAB1 and MPN was almost identical in
strength, but was slightly weaker than that of wildtype
MIF. However, this diﬀerence was not statistically signiﬁ-
cant. Together, this indicated that the tautomerase site
around residue Pro-2 is not critical for the binding of MIF
to JAB1 and MPN.3.3. The MIF–MPN interaction occurs in vivo at endogenous
protein concentrations
The MIF–JAB1 interaction was previously shown to occur
in mammalian cells and to mediate modulation of JAB1 activ-
ity by MIF [35]. To test whether binding of MIF to the MPN
domain occurs in a physiologically relevant environment such
as in a mammalian cell, and thus is relevant for the interaction
between MIF and JAB1 in vivo, we next investigated whether
MIF was able to bind to an MPN domain-containing protein
in the cell that was distinct from JAB1. CSN6, another subunit
of the CSN, was elected as its MPN domain exhibits an ex-
tended homology to the JAB1 MPN domain. CoreMPN spans
a major part of this homology region (Fig. 4A). The potential
interaction between MIF and CSN6 was examined by CoIP
Fig. 3. Interaction of MIF peptide 50–65 with MPN as demonstrated
by CoIP and nanobead aﬃnity mass spectrometry. Biotin-labeled
MIF(50–65) was incubated with in vitro-translated coreMPN and
complexes precipitated by streptavidin nanobead aﬃnity pull-down.
For comparison, incubations were performed with the bis-serine
variant of MIF(50–65) and for negative control, with beads alone.
Precipitates were directly subjected to MALDI-MS as described in
Section 2. Upper/red spectrum: incubation of biotin-MIF(50–65) with
MPN; middle/blue: incubation of bis-serine variant of biotin-MIF(50–
65) with MPN; bottom/black: control incubation without biotinylated
peptide. MALDI-MS signals are given as relative units. In addition to
the M + H peaks of MPN, the M + 2H peak of MPN, peaks for the
biotinylated MIF peptides and streptavidin were detected as indicated.
Fig. 2. Coimmunoprecipitation of protein complexes of rMIF and
in vitro-translated MPN. Bacterially expressed puriﬁed recombinant
MIF was incubated with 35S-labeled coreMPN domain produced by in
vitro transcription/translation, and protein complexes were immuno-
precipitated by anti-MIF antibody (anti-MIF) in comparison
to control incubations without antibody. Coprecipitated MPN was
revealed by gel electrophoresis and autoradiography. As input control
for the CoIP, 10% of the amount of 35S–MPN used was electropho-
resed for comparison.
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anti-CSN6 antibody for CoIP. Fig. 4B demonstrates that a
marked MIF band was coprecipitated by the anti-CSN6 anti-
body, whereas a control incubation with beads alone only led
to a minor band due to some residual non-speciﬁc adsorption.
This indicated that MIF–CSN6 protein complexes form intra-
cellularly at physiological conditions and non-overexpressed
endogenous concentrations of both components. At the same
time, this analysis demonstrated that the MPN domain is suf-
ﬁcient in vivo to mediate MIF–JAB1 interaction and that a
MIF–CSN6 interaction occurs in vivo. Comparison with a
CoIP of endogenous MIF–JAB1 complexes revealed that for-
mation of the MIF–CSN6 complexes was slightly weaker than
that of the MIF–JAB1 complexes. Since CSN6 does not con-
tain a functional JAMM motif within its MPN domain (Fig.
4A), endogenous formation of MIF–CSN6 complexes con-
ﬁrmed that the JAMM motif and JAMM-mediated isopepti-
dase activity were not necessary for binding of MIF to JAB1.In summary, these data showed that the MPN domain inde-
pendent of its JAMM function is suﬃcient to mediate MIF–
JAB1 interaction in vitro and in vivo, that, on the side of
MIF, sequence 50–65 accounts for the binding to MPN, and
that MIF also binds to CSN6 in a MPN-dependent fashion.4. Discussion
Macrophage migration inhibitory factor critically partici-
pates in the regulation of the host inﬂammatory response.
Originally, MIF was thought to predominantly regulate cell
migration, but today it is known that MIF-driven eﬀects
encompass a broad spectrum of typical cytokine-mediated ef-
fects on cell proliferation, cell apoptosis, cell cycle arrest,
and transcriptional induction of a variety of genes [21]. Mod-
ulation of immune cell function by MIF is often proinﬂamma-
tory and includes stimulation of cell proliferation and MAPK
kinase signaling in a CD74-dependent manner [21,29].
On the other hand, it appears that MIF utilizes the JAB1-
mediated signaling pathway to ﬁne-tune an antiinﬂammatory
cellular response [35,41]. Cell regulation by MIF through
JAB1 is either initiated by preformed intracellular MIF or oc-
curs upon endocytosis of extracellular MIF into target cells
[35,42]. The details of both the CD74- and JAB1-mediated sig-
naling pathways still need to be unraveled. As to the JAB1-
mediated pathway, it will be important to understand the
mechanism of MIF–JAB1 interaction, as for example, MIF
binding to JAB1 could interfere with recognition by JAB1 of
neddylated substrates or subcellular transportation and deliv-
ery to the CSN, which then might be responsible for further
signal transduction regulatory processes [20,43]. While it has
become evident that MIF sequence 50–65 participates in
MIF–JAB1 interaction, it has been unknown which sequence
region or domain of JAB1 is responsible for binding to MIF.
Deﬁning the interaction modules on both binding partners will
be important to further characterize the mechanism of JAB1-
mediated cell regulation by MIF.
In the current study, we have demonstrated that the MPN
domain of JAB1, which was previously demonstrated to medi-
ate the binding of JAB1 to p27 and topoisomerase IIa, is
responsible both in vitro and in vivo for the binding of MIF
to JAB1. Since we have used a core MPN domain that did
not encompass the functional JAMM motif, it is apparent that
the JAMM site and activity is not necessary for MIF binding.
Binding of the MIF-agonistic peptide 50–65 and its bis-serine
variant to MPN further indicated that sequence regions MIF
50–65 and JAB1 53–142 represent minimal regions enabling
for an interaction between MIF and JAB1. Future structure
activity studies will need to be performed to deﬁne the binding
aﬃnities between these modules and to examine whether
longer or shorter regions will lead to an increase or decrease
in the interaction.
Interaction between MIF and the core MPN region of JAB1
was ﬁrst demonstrated by YTH analysis by both plate assay
and the quantitative liquid media assay. Of note, the interac-
tion between MIF and coreMPN was comparable to that be-
tween MIF and full-length JAB1 [35], indicating that the
elected MPN region contained the minimal interaction region
required. Nevertheless, since YTH screens can lead to false-
positive results and because truncation of MPN might have
Fig. 4. Interaction of endogenous MIF with endogenous MPN in vivo and independency of the MIF–MPN interaction of the JAMM motif.
(A) Scheme of the MPN domain of JAB1/CSN5 and homology with the core MPN domain used in Figs. 1–3 of this study and the MPN domain of
CSN6. The core MPN domain (cMPN) spans JAB1 residues 53–142. For JAB1/CSN5, the positions of the residues forming the JAMM motif are
indicated. The MPN domain of CSN6 does not contain a JAMM motif. (B) Endogenous coimmunoprecipitation of MIF–CSN6 complexes and
comparison with MIFJAB1/CSN5 complexes. Top two panels: Immunoprecipitation of CSN6 complexes with anti-CSN6 antibody and detection of
coprecipitated MIF by Western blot analysis (upper panel). For control, CoIPs were performed with beads alone. One-tenth of the CoIP incubation
sample was co-electrophoresed as input-control. Blot was stripped after MIF detection and re-developed with anti-CSN6 to control for CoIP
eﬃciency (middle panel). Lower panel: for comparison, endogenous MIF–JAB1 complexes were coimmunoprecipitated using anti-JAB1 antibody.
Western blot analysis was performed as above.
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interaction in the yeast system, MIF–MPN binding was con-
ﬁrmed by protein–protein interaction studies in vitro. These
studies demonstrated that puriﬁed biologically active MIF
formed speciﬁc complexes with in vitro-translated coreMPN.
The previous studies investigating the role of MPN in JAB1
binding to p27 and topoisomerase IIa have applied the entire
N-terminus of JAB1 spanning residues 1–190 and covering
the JAMM site [18,19]. Our study demonstrates that for
JAB1 interaction with MIF, a shorter sequence stretch is suf-
ﬁcient and that the JAMM site or activity is not needed. That
MIF–MPN binding occurs physiologically in a mammalian
cell was further shown by endogenous CoIP between MIF
and another MPN-containing mammalian protein, the CSN
component CSN6. As CSN6 does not contain a JAMM site,
this experiment also provided in vivo evidence that MIF–
JAB1 interaction is JAMM-independent.
Recently, thioredoxin (Trx) an enzyme and co-cytokine
[44,45] that shares with MIF its TPOR catalytic activity and
redox-based anti-apoptotic function [33,46] was found to bind
to JAB1 and to regulate JAB1-mediated cell functions in a
manner essentially identical to that of MIF [47], indicating that
MIF and Trx might not only share redox-regulatory activities
and cytokine-like functions, but might also interact with JAB1
in a similar manner. However, JAB1 binds to Trx through itsC-terminal region independent of MPN [47]. Thus, MIF and
Trx both regulate JAB1 functions in a similar fashion, but
the initial molecular binding event is diﬀerent between these
two mediators. It will be interesting to investigate whether
the binding of MIF to JAB1 can nevertheless interfere with
JAB1–Trx interaction or vice versa, or whether the respective
interactions represent independent processes.
Binding of MIF(50–65) to MPN conﬁrmed our prior obser-
vations that the sequence region around the CXXC motif of
MIF is critical for interaction with JAB1 [35]. As also the
bis-serine variant of this peptide bound to MPN, these studies
in addition conﬁrmed that it is the sequence region itself inde-
pendent of the presence of the two Cys residues that confers
binding to JAB1 [34]. Although we did not observe an interac-
tion for the C60SMIF mutant in the YTH assay, the latter
conclusion is nevertheless likely to hold true. C60SMIF has
previously been shown to bind to JAB1 [35], and since it was
also demonstrated that C60SMIF has a high tendency to
aggregate when expressed in cells not containing endogenous
MIF such as in E. coli [37], we suggest that the lack of interac-
tion is due to aggregation/misfolding/degradation processes.
This will need to be investigated further in the future. In line
with the notion that the sequence region around the CXXC
motif is important for MIF–MPN binding, we observed that
P2AMIF, a MIF variant with a mutation in the N-terminal
1700 A. Burger-Kentischer et al. / FEBS Letters 579 (2005) 1693–1701isomerase site of MIF, bound to JAB1 and MPN comparably
to the wildtype protein. Thus, the N-terminal site does not ap-
pear to be involved in the interaction.
In conclusion, we have identiﬁed a core MPN module of
JAB1 as the binding region for MIF. MIF binding to JAB1
is JAMM-independent and occurs in vivo. The data further
suggest that MIF not only binds to the CSN component
JAB1/CSN5 but can also interact with CSN6. Since the
MIF–CSN6 interaction is somewhat weaker than that between
MIF and JAB1/CSN5, it may be implied that JAB1 is the ma-
jor interaction partner of MIF in the cell, but that additional
weaker interactions occur with other MPN domain-containing
proteins. The precise interplay between these binding partners
and the corresponding biological eﬀects are likely to be criti-
cally involved in a variety of cell functions and will thus be
worthwhile of exploring.Acknowledgments: We thank A. Kapurniotu for synthesizing the bio-
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